Antimacrophage chemokine treatment prevents neutrophil and macrophage influx in hyperoxia-exposed newborn rat lung

Michael A. Vozzelli,1 S. Nicholas Mason,1 Mary H. Whorton,1 and Richard L. Auten, Jr.1,2

1Department of Pediatrics, Division of Neonatal Medicine, Neonatal-Perinatal Research Institute, Duke University Medical Center, Durham 27710; and 2Comprehensive Center for Inflammatory Disorders, University of North Carolina at Chapel Hill, School of Dentistry, Chapel Hill, North Carolina 27510

Submitted 3 December 2002 ; accepted in final form 10 February 2003


    ABSTRACT
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Macrophage-derived cytokines may provoke the inflammatory response in lung injury. Because macrophage influx is a prominent feature of the cellular inflammatory response accompanying the development of bronchopulmonary dysplasia, we hypothesized that blocking macrophage influx would reduce overall cellular influx and oxidative damage. Newborn rats were exposed at birth to 95% O2 or air for 1 wk, and hyperoxia-exposed pups were injected with anti-monocyte chemoattractant protein-1 (MCP-1) or IgG control on days 3–5. MCP-1 was increased in bronchoalveolar lavage fluid and in histological sections from the 95% O2-exposed, IgG-injected pups compared with air-exposed controls. At 1 wk, anti-MCP-1-treated pups had reduced leukocyte numbers, both macrophages and neutrophils, in bronchoalveolar lavage fluid compared with IgG-treated controls. Cytokine-induced neutrophil chemoattractant-1, the rat analog of IL-8, was not significantly decreased in lavage fluid but was reduced in lung cells in anti-MCP-1-treated pups. Tissue carbonyls, a measure of protein oxidation, were decreased in anti-MCP-1-treated pups. Anti-MCP-1 treatment prevented neutrophil influx and reduced protein oxidation in hyperoxia-exposed newborn rats.

bronchopulmonary dysplasia; oxidative stress; white blood cell


EARLY INFLAMMATION MAY CONTRIBUTE to disrupted lung development in premature newborns who later develop bronchopulmonary dysplasia (BPD). Elevations of leukocyte chemokines have been observed in tracheal aspirates of newborns who later develop BPD (21, 22). Elevations of monocyte chemoattractant protein-1 (MCP-1), for example, have been associated with the development of BPD (2).

Macrophages are important sources of leukocyte chemokines, such as chemokine cytokine-induced neutrophil chemoattractant-1 (CINC-1) and macrophage inflammatory protein-2 (MIP-2) in rats (13) and interleukin-8 (IL-8) and growth-related oncogene-{alpha} in humans (23). They are among the first extrapulmonary cells to infiltrate following injury and during acute infant respiratory distress syndrome (19). Hyperoxia exposure is used to model the oxidative stress experienced by newborns who develop BPD, since it produces neutrophil and macrophage influx, followed by disrupted alveolar development (1, 9, 29). Hyperoxia induces MCP-1 expression in several species (10, 11, 15). Blocking macrophage influx by neutralizing MCP-1 may therefore reduce neutrophil influx and reduce oxidative damage.

We hypothesized that early treatment with neutralizing antibody against MCP-1 would prevent both neutrophil and macrophage accumulation in the airways of hyperoxia-exposed newborn rats. We found that hyperoxia induced elevated MCP-1 expression in newborn rats, particularly in bronchiolar and alveolar epithelium. Anti-MCP-1 treatment reduced both macrophage and neutrophil accumulation in hyperoxia-exposed newborn rat lungs. CINC-1 was diminished in airway epithelium following anti-MCP-1 treatment, as was protein oxidation.


    METHODS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Animals. All procedures were approved by the Institutional Animal Care and Use Committee. Timed-pregnant Sprague-Dawley rats were exposed on the day of delivery to air or 95% oxygen along with recombined litters as previously described (13). Nursing dams were exchanged daily between air- and hyperoxia-exposed litters. Litter size was adjusted to maintain numerical balance among litters.

MCP-1 expression. Air- and hyperoxia-exposed pups were killed on days 2, 4, 6, and 7 with an overdose of pentobarbital sodium given intraperitoneally, and we perfused the pulmonary artery with 0.9% NaCl and 1 mM EDTA, pH 7.5, after clipping the left atrium. A tracheal cannula was ligated in place, and four 0.5-ml bronchoalveolar lavages (BAL) were slowly performed, and the samples were pooled. After centrifugation at 2,000 g for 10 min, supernatants were snap-frozen in liquid nitrogen and later analyzed for rat MCP-1 by ELISA with a commercial kit (Opt-EIA; Pharmingen, San Diego, CA). To evaluate the effects of hyperoxia on histochemical expression of MCP-1, we killed air- and oxygen-exposed animals on day 7, and lungs were inflation fixed at 30 cmH2O pressure for 30 min and then immersed overnight in 10% phosphate-buffered formalin, paraffin embedded, and sectioned at 4-µm thickness. Random sections were incubated with rabbit anti-MCP-1 (1:1,000; Torrey Pines Biolabs, Houston, TX) or nonimmune rabbit serum as a negative control and then detected with goat-anti-rabbit biotin (1:1,000) followed by substrate visualization with the ABC Elite system and VIP peroxidase color substrate (Vector, Burlingame, CA). Sections were counterstained with methyl green. Three sections from three animals group were evaluated.

Anti-MCP-1 treatment. On days 3, 4, and 5, hyperoxia-exposed pups, n = 10/group, were injected daily with 0.1 ml of PBS, pH 7.4, containing control (vehicle only), 5 or 25 µg of rabbit anti-rat MCP-1, a neutralizing antibody (Torrey Pines Biolabs), or 5 µg of nonimmune rabbit IgG given intraperitoneally. Exposures continued until animals were killed on day 7.

BAL fluid analysis. BAL fluid (BALF) was obtained as above, and cells were counted with a hemacytometer. At least 200 cells/animal were evaluated following cytospin and modified Wright's staining. Pooled BALF supernatants from each pup were snap-frozen in liquid nitrogen for cytokine analysis.

CINC-1 expression. CINC-1 concentrations were measured in BALF from 10 animals in each treatment condition by an ELISA we previously described in detail (1). Plates were coated with a goat-antirat CINC-1 antibody (Chemicon, Temecula, CA), blocked with 5% nonfat milk in PBS, and then incubated with BALF overnight at 4°C. Plates were washed and incubated with rabbit anti-rat CINC-1 (R&D Systems, Minneapolis, MN) and then anti-rabbit-peroxidase conjugate. We then detected CINC-1 histochemical expression using goat anti-rat CINC-1 polyclonal antibody as we previously described in detail (13). We chose three random sections from three animals in each treatment group: air-, hyperoxia-exposed, and hyperoxia + 25 µg anti-MCP-1 treatment.

Protein carbonyl measurement. To determine the effect of anti-MCP-1 treatment on oxidant stress during hyperoxia exposure, we homogenized lungs in an anti-protease cocktail (Complete, Roche) with an antioxidant, butyl-hydroxytoluene. Homogenates were derivitized with dinitrophenylhydrazine (DNPH) to detect carbonyl residues formed by protein oxidation. Homogenates were reacted with 10 mM DNPH in 6 M guanidine hydrochloride, 0.5 M potassium phosphate buffer, pH 2.5, and the DNPH-derivitized proteins were detected by ELISA using the method described by Buss et al. (5).

Statistical analysis. Results are expressed as means ± SE. Treatment group differences were compared with ANOVA, and significant differences were identified by post hoc analysis using Tukey-Kramer. Significance was accepted at P < 0.05, assuming an {alpha}-error = 0.05 and {beta}-error = 0.10.


    RESULTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Hyperoxia-exposed rats were smaller than air-exposed rats (14.5 ± 0.2 vs. 16.5 ± 0.3 g, P < 0.001, n = 20/group). There were no significant differences among the oxygen-exposed control groups, and there was no effect of anti-MCP-1 at either dose on body weight. There was mortality only in the oxygen-exposed groups (air: n = 188, 100% survival; hyperoxia: n = 200, 93% survival; P = 0.0001) and no differences in mortality among each of the oxygen-exposed treatment groups.

MCP-1 expression. 95% O2 exposure significantly induced MCP-1 accumulation in BALF at all time points measured, with a doubling at day 2, and between fifteen- and fifty-fold increases at days 4, 6, and 7 (n = 9/group, Fig. 1).



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1. Effect of air and 95% O2 on monocyte chemoattractant protein-1 (MCP-1) concentrations in bronchoalveolar lavage fluid (BALF). Results are means ± SE, n = 9/group.

 

MCP-1 immunostaining was plainly apparent in bronchiolar and alveolar epithelium, and staining in both of these cell types was increased by 95% O2 exposure at 1 wk (Fig. 2). Both ciliated and nonciliated bronchiolar epithelium were labeled, and higher magnification views showed septal-tip staining, particularly in the hyperoxia-exposed animals. We did not quantify staining differences among cell types.



View larger version (140K):
[in this window]
[in a new window]
 
Fig. 2. Effect of 95% O2 on MCP-1 immunostaining in alveolar and bronchiolar epithelium. Air (A, C) vs. 95% O2 (B, D) x 1 wk; magnification x100 (A, B) and x400 (C, D). Purple precipitate indicates signal, methyl green counterstain.

 

Anti-MCP-1 treatment: BALF leukocytes. Hyperoxia (control, sham, and IgG-injected) induced significant increases in BALF leukocytes, both neutrophils and macrophages. Anti-MCP-1 treatment at both doses significantly reduced the BALF neutrophil counts, n = 6/group. Only pups injected with 25 µg of anti-MCP-1 showed reductions in total and macrophage cell counts, as well as neutrophil counts (Fig. 3).



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3. Effect of anti-MCP-1 treatment on BALF leukocytes at day 7 of air or hyperoxia exposure. Macs, macrophages; PMNs, neutrophils. Results are means ± SE, n = 6/group.

 

Anti-MCP-1 effect on CINC-1 expression. Hyperoxia induced significant increases in CINC-1 in BALF. At the highest dose, anti-MCP-1 reduced CINC-1 concentrations in BALF, although this did not reach statistical significance (Fig. 4). CINC-1 expression was increased in both alveolar and bronchiolar epithelium, as well as in macrophages in hyperoxia-exposed rats compared with air-exposed rats. Anti-MCP-1 treatment decreased CINC-1 expression in all cell types (Fig. 5), although this was not strictly quantified.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 4. Effect of anti-MCP-1 treatment on cytokine-induced neutrophil chemoattractant-1 (CINC-1) concentration in BALF. Results are means ± SE, n = 6/group.

 


View larger version (99K):
[in this window]
[in a new window]
 
Fig. 5. Effect of anti-MCP-1 on CINC-1 immunolabeling in bronchiolar and alveolar epithelium. Final magnification top, x100; bottom, x200. Brown precipitate indicates signal, hematoxylin counterstain. Arrows, bronchiolar epithelium; arrowheads, alveolar epithelium and alveolar macrophages.

 

Anti-MCP-1 treatment: protein carbonyls. Hyperoxia induced significant increases in lung homogenate protein carbonyls detected by DNPH derivitization. Anti-MCP-1 at 5 µg had no effect but at 25 µg completely prevented the hyperoxia-induced increase in carbonyls (Fig. 6).



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 6. Effect of anti-MCP-1 on protein oxidation measured as protein carbonyl concentration in lung homogenates. DNPH, dinitrophenylhydrazine. Results are means ± SE, n = 5/group.

 


    DISCUSSION
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
We have shown that blockade of hyperoxia-induced MCP-1 with neutralizing antibodies can prevent both macrophage and neutrophil accumulation in the lungs of hyperoxia-exposed newborn rats. This resulted, at the highest anti-MCP-1 dose, in reduced protein oxidation in lung tissue at the highest dose. There were also effects on BALF leukocytes and neutrophils at the lower anti-MCP-1 dose that were not apparent in saline- or nonimmune IgG-treated control groups. We did not administer nonimmune IgG at the higher 25-µg dose, so we cannot completely exclude nonspecific effects of IgG that we believe are nevertheless unlikely. Indeed, intermediate or higher anti-MCP-1 doses or pretreatment with anti-MCP-1 may be as effective or more effective. Resident alveolar macrophages and recruited macrophages take part in host defense following lung injury. Clinical and experimental studies have demonstrated prompt influx of macrophages in newborn lung injury, particularly respiratory distress syndrome (7, 19). Recruitment of macrophages is under the control of macrophage chemokines such as MCPs 1–4 and MIP-1{alpha}, some of which chemoattract macrophages through receptors CC-R1 and CC-R2 (23). The relative contribution of each of the potential macrophage chemoattractant pathways may differ depending on the inflammatory stimulus.

Hyperoxia has previously been shown to stimulate MCP-1 mRNA and protein accumulation in the lung in a number of species, in both adults and newborns (1012, 15, 20). Likewise, lung injury induced by mechanical ventilation also increased MCP-1 (6). Clinical studies have implicated its participation in neonatal lung injury associated with BPD (2).

Blockade of MCP-1 or its receptors has had mixed results, depending on the injury model. Anti-MCP-1 did not affect macrophage or neutrophil recruitment in a model of immune complex-induced lung injury in adult rats (3). Lethality was increased along with decreased IL-10 and increased TNF-{alpha} and IL-12 in adult mice given anti-MCP-1 before endotoxin challenge. The reverse trends were observed in mice given exogenous MCP-1 (30). Because macrophages are necessary for clearance of apoptotic neutrophils (17), it may be that premature blockade of macrophage influx permitted neutrophils to proceed to necrosis, leading to elaboration of damaging proteases.

We thought that decreasing macrophage influx might decrease neutrophil influx by decreasing a significant cellular source of neutrophil chemokines (13). Although there was a trend toward reduced CINC-1 in BALF in anti-MCP-1-treated rats that did not achieve significance, we did note decreased alveolar and bronchiolar epithelial CINC-1 immunohistochemical labeling in high-dose anti-MCP-1 95% O2-exposed rats. We did not test for the presence of other chemokines that are secreted by macrophages, such as MIP-2, which could be influencing neutrophil recruitment.

Decreasing macrophage and monocyte activation by treatment with anti-MCP-1 could have reduced neutrophil influx in other ways. Maus and colleagues (24) have shown that MCP-1-stimulated monocyte influx without accompanying injury does not provoke neutrophil emigration into the lung. However, selective depletion of already resident alveolar macrophages did reduce airway neutrophil recruitment and neutrophil chemokine in an endotoxin injury model (26). It may be that sequential analysis of neutrophil chemokine abundance and localization of expression would clarify mechanisms of neutrophil-macrophage cross talk in this model, since neutrophils themselves secrete neutrophil (16) and macrophage chemokines (14).

In contrast, we observed no anti-MCP-1-associated differences in mortality among the hyperoxia-exposed newborn rats or significant blockade of both macrophages and neutrophils at the highest anti-MCP-1 dose in our model of newborn lung injury. Because the hyperoxia effects are less intense than those provoked by endotoxin (chemokine elevations accumulate in days, not hours), the contribution of macrophages to counterregulate or resolve acute inflammation may be relatively less important.

The nature of the injury is likely to determine the effect of macrophage blockade. If the macrophages themselves are principal sources of neutrophil chemokines, then it may explain why anti-MCP-1 had beneficial results in our model. Maus and colleagues (25) found that knockout mice lacking CC-R2, a principal MCP-1 receptor, did not mobilize neutrophils in response to intratracheal lipopolysaccharide (LPS). They also found that the physiological benefits of MCP-1 blockade were neutrophil dependent (26). This is consistent with our finding that neutrophils and CINC-1 were reduced in animals that received the highest anti-MCP-1 dose. Likewise, protein oxidation, likelier to result from neutrophil than macrophage activation, was similarly reduced. Blocking macrophage influx alone may not abrogate an injury such as LPS exposure that provokes massive endothelial and epithelial expression of proinflammatory cytokines.

Timing of maneuvers designed to block macrophage influx may also be crucial. For example, resolution of pulmonary inflammation, particularly clearance of neutrophils, depends on neutrophil signaling of alveolar macrophages (27). Late administration of antimacrophage chemokine antibodies might delay resolution of inflammation, possibly allowing damaging contents of neutrophils to persist in the lung. Anti-MCP-1 might accelerate clearance of already resident macrophages, since macrophage survival following activation may depend on continued MCP-1 transduction (18).

Chronic lung inflammation may lead to pathological repair that is accompanied by failed alveolization and fibrosis (8). Repair depends on macrophage-expressed mitogens such as platelet-derived growth factor and others (4), but the timing of these processes is not well understood (27). It is conceivable that attenuation of late macrophage influx could interrupt maladaptive repair, preventing the development of pulmonary fibrosis, as has been done in bleomycin-challenged mice treated with antimacrophage chemokines (28).

In conclusion, we report that hyperoxia-induced pulmonary leukocyte accumulation in newborn mice can be partly prevented by treatment with anti-MCP-1. At the highest dose, anti-MCP-1 also prevented protein oxidation in lungs from hyperoxia-exposed mice. We speculate that properly timed administration of macrophage chemokine blockade can attenuate inflammation and its consequent biomolecular damage, which impairs lung development in BPD.


    ACKNOWLEDGMENTS
 
The authors acknowledge the technical assistance of Kathryn M. Auten.

GRANTS

The work was supported by a grant from the Children's Miracle Network (M. A. Vozzelli) and National Heart, Lung, and Blood Institute Grant HL-67021 (R. L. Auten).


    FOOTNOTES
 

Address for reprint requests and other correspondence: R. L. Auten, DUMC, Box 3373, Durham, NC 27710 (E-mail: auten{at}duke.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Auten RL Jr, Mason SN, Tanaka DT, Welty-Wolf K, and Whorton MH. Anti-neutrophil chemokine preserves alveolar development in hyperoxia-exposed newborn rats. Am J Physiol Lung Cell Mol Physiol 281: L336-L344, 2001.[Abstract/Free Full Text]
  2. Baier RJ, Loggins J, and Kruger TE. Monocyte chemoattractant protein-1 and interleukin-8 are increased in bronchopulmonary dysplasia: relation to isolation of Ureaplasma urealyticum. J Investig Med 49: 362-369, 2001.[CrossRef][ISI][Medline]
  3. Bless NM, Huber-Lang M, Guo RF, Warner RL, Schmal H, Czermak BJ, Shanley TP, Crouch LD, Lentsch AB, Sarma V, Mulligan MS, Friedl HP, and Ward PA. Role of CC chemokines (macrophage inflammatory protein-1 beta, monocyte chemoattractant protein-1, RANTES) in acute lung injury in rats. J Immunol 164: 2650-2659, 2000.[Abstract/Free Full Text]
  4. Brandes ME and Finkelstein JN. The production of alveolar macrophage-derived growth-regulating proteins in response to lung injury. Toxicol Lett 54: 3-22, 1990.[CrossRef][ISI][Medline]
  5. Buss H, Chan TP, Sluis KB, Domigan NM, and Winterbourn CC. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 23: 361-366, 1997.[CrossRef][ISI][Medline]
  6. Cheng KC, Zhang H, Lin CY, and Slutsky AS. Ventilation with negative airway pressure induces a cytokine response in isolated mouse lung. Anesth Analg 94: 1577-1582, 2002.[Abstract/Free Full Text]
  7. Coalson J. Neonatal chronic lung disease in extremely premature baboons. Am J Respir Crit Care Med 160: 1333-1346, 1999.[Abstract/Free Full Text]
  8. Coalson J. Pathology of chronic lung disease of early infancy. In: Chronic Lung Disease in Early Infancy, edited by Bland RD and Coalson J. New York: Dekker, 2000, p. 85-124.
  9. Coalson JJ. Experimental models of bronchopulmonary dysplasia. Biol Neonate 71: 35-38, 1997.[ISI][Medline]
  10. D'Angio CT, Johnston CJ, Wright TW, Reed CK, and Finkelstein JN. Chemokine mRNA alterations in newborn and adult mouse lung during acute hyperoxia. Exp Lung Res 24: 685-702, 1998.[ISI][Medline]
  11. D'Angio CT, LoMonaco MB, Chaudhry SA, Paxhia A, and Ryan RM. Discordant pulmonary proinflammatory cytokine expression during acute hyperoxia in the newborn rabbit. Exp Lung Res 25: 443-465, 1999.[CrossRef][ISI][Medline]
  12. D'Angio CT, Sinkin RA, LoMonaco MB, and Finkelstein JN. Interleukin-8 and monocyte chemoattractant protein-1 mRNAs in oxygen-injured rabbit lung. Am J Physiol Lung Cell Mol Physiol 268: L826-L831, 1995.[Abstract/Free Full Text]
  13. Deng H, Mason SN, and Auten RL. Lung inflammation in hyperoxia can be prevented by anti-chemokine treatment in newborn rats. Am J Respir Crit Care Med 162: 2316-2323, 2000.[Abstract/Free Full Text]
  14. Diab A, Abdalla H, Li HL, Shi FD, Zhu J, Hojberg B, Lindquist L, Wretlind B, Bakhiet M, and Link H. Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. Infect Immun 67: 2590-2601, 1999.[Abstract/Free Full Text]
  15. Ekekezie II, Thibeault DW, Garola RE, and Truog WE. Monocyte chemoattractant protein-1 and its receptor CCR-2 in piglet lungs exposed to inhaled nitric oxide and hyperoxia. Pediatr Res 50: 633-640, 2001.[Abstract/Free Full Text]
  16. Gillitzer R, Ritter U, Spandau U, Goebeler M, and Brocker EB. Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 107: 778-782, 1996.[Abstract]
  17. Haslett C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med 160: S5-S11, 1999.[Abstract/Free Full Text]
  18. Horiguchi T, Shibata MA, Ito Y, Eid NA, Abe M, and Otsuki Y. Macrophage apoptosis in rat skeletal muscle treated with bupivacaine hydrochloride: possible role of MCP-1. Muscle Nerve 26: 79-86, 2002.[CrossRef][ISI][Medline]
  19. Jackson JC, Chi EY, Wilson CB, Truog WE, Teh EC, and Hodson WA. Sequence of inflammatory cell migration into lung during recovery from hyaline membrane disease in premature newborn monkeys. Am Rev Respir Dis 135: 937-940, 1987.[ISI][Medline]
  20. Johnston CJ, Wright TW, Reed CK, and Finkelstein JN. Comparison of adult and newborn pulmonary cytokine mRNA expression after hyperoxia. Exp Lung Res 23: 537-552, 1997.[ISI][Medline]
  21. Kotecha S, Chan B, Azam N, Silverman M, and Shaw RJ. Increase in interleukin-8 and soluble intercellular adhesion molecule-1 in bronchoalveolar lavage fluid from premature infants who develop chronic lung disease. Arch Dis Child Fetal Neonatal Ed 72: F90-F96, 1995.[Abstract]
  22. Kotecha S, Wilson L, Wangoo A, Silverman M, and Shaw RJ. Increase in interleukin (IL)-1 beta and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res 40: 250-256, 1996.[Abstract]
  23. Luster AD. Chemokines–chemotactic cytokines that mediate inflammation. N Engl J Med 338: 436-445, 1998.[Free Full Text]
  24. Maus U, Huwe J, Maus R, Seeger W, and Lohmeyer J. Alveolar JE/MCP-1 and endotoxin synergize to provoke lung cytokine upregulation, sequential neutrophil and monocyte influx, and vascular leakage in mice. Am J Respir Crit Care Med 164: 406-411, 2001.[Abstract/Free Full Text]
  25. Maus U, von Grote K, Kuziel WA, Mack M, Miller EJ, Cihak J, Stangassinger M, Maus R, Schlondorff D, Seeger W, and Lohmeyer J. The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice. Am J Respir Crit Care Med 166: 268-273, 2002.[Abstract/Free Full Text]
  26. Maus UA, Koay MA, Delbeck T, Mack M, Ermert M, Ermert L, Blackwell TS, Christman JW, Schlondorff D, Seeger W, and Lohmeyer J. Role of resident alveolar macrophages in leukocyte traffic into the alveolar air space of intact mice. Am J Physiol Lung Cell Mol Physiol 282: L1245-L1252, 2002.[Abstract/Free Full Text]
  27. Sherman MP and Truog WE. The role of pulmonary macrophages in chronic lung disease of early infancy. In: Chronic Lung Disease in Early Infancy, edited by Bland RD and Coalson J. New York: Dekker, 2000, p. 813-839.
  28. Smith RE, Strieter RM, Zhang K, Phan SH, Standiford TJ, Lukacs NW, and Kunkel SL. A role for C-C chemokines in fibrotic lung disease. J Leukoc Biol 57: 782-787, 1995.[Abstract]
  29. Warner BB, Stuart LA, Papes RA, and Wispe JR. Functional and pathological effects of prolonged hyperoxia in neonatal mice. Am J Physiol Lung Cell Mol Physiol 275: L110-L117, 1998.[Abstract/Free Full Text]
  30. Zisman DA, Kunkel SL, Strieter RM, Tsai WC, Bucknell K, Wilkowski J, and Standiford TJ. MCP-1 protects mice in lethal endotoxemia. J Clin Invest 99: 2832-2836, 1997.[Abstract/Free Full Text]